A malaria vaccine showing up to 90% protection in early clinical studies and a key question: how does it work? That’s what the European CAPTIVATE consortium is working on. BPRC is a partner.

https://lnkd.in/ekNSR4Jw

In Antwerp, researchers from across Europe came together to share progress and align next steps.

The CAPTIVATE consortium approach is fundamentally different. Instead of using fragments of the parasite, this vaccine uses a genetically attenuated version of the malaria parasite itself.

After vaccination, the parasite reaches the liver, but stops there. It cannot develop further. This allows the immune system to recognise and eliminate the parasite at the earliest stage, before it causes disease.

“The strong protection seen in healthy volunteers often doesn’t translate to endemic settings”, says Erica Pasini (BPRC). “We want to understand why and how to make it work where it matters most.”

At BPRC, we contribute by studying immune responses in greater depth, helping to bridge the gap between controlled studies and real-world impact. During the meeting, scientists shared the latest developments. Key project milestones have already been reached, and the work is in full swing!

Next step: in June, the first results of the non-human primate trial will become available along with key samples to further investigate the immune mechanisms behind protection.

#CAPTIVATE #MalariaResearch #VaccineDevelopment #BPRC #EUfunded

bart faber Eva Iliopoulou Gemma Hartley Catherine Moreau Blandine Franke-Fayard Sander Wuyts, PhD 🧬 Cynthia Crul

Things to Do and Not to Do When Vaccinating Birds 🐓💉


✅ Things to Do When Vaccinating Birds
Use healthy birds only – Vaccinate only birds that are active and disease-free.Only vaccinate healthy birds; postpone vaccination if the flock is showing signs of illness.
Follow vaccination schedule – Give vaccines at the correct age and time.
Maintain cold chain (2–8°C) – Keep vaccines in a refrigerator or ice pack.Bring them out of the cooler only when ready to use.
Use clean water for vaccines – Especially for drinking-water vaccines.
Use sterile equipment – Clean syringes and droppers should be used.
Read manufacturer’s instructions – Follow dosage and method carefully.
Vaccinate early in the morning or evening – Avoid heat stress.
Withhold water for 1-4 hours before vaccination to ensure birds are thirsty.
Mix vaccine properly – Ensure even distribution in water or solution.
Consider adding skim milk powder (about 2g per liter) to stabilize the vaccine.
Ensure the vaccine is consumed within 1-2 hours.
Record vaccination details – Date, vaccine name, age of birds, batch number.
Walk through the house to encourage birds to move around and drink or if in Battery cage system, ensure the nipples are not blocked.
Observe birds after vaccination – Monitor for reactions or stress.

❌ Things Not to Do When Vaccinating Birds
Do not vaccinate sick birds – It may worsen their condition.
Do not use expired vaccines – They will not work effectively.
Do not expose vaccines to sunlight or heat – This destroys the vaccine.
Do not mix vaccines with dirty water – It reduces effectiveness.
Do not use antibiotics before or after vaccination – May affect vaccine response.
Do not overcrowd birds during vaccination – Causes stress.
Do not open vaccine long before use – Use immediately after opening.
Do not use chlorinated water – Chlorine kills live vaccines.
Do not skip booster doses – Immunity will be weak.
Do not vaccinate during extreme weather – Heat or cold affects immunity.

#GoodManagementPractices
#DiseasePrevention
#HealthyLivestock
#ImprovedProfitability
#BetterSuistainability
#PublicHealth

#MeaslesVaccine #LiveAttenuatedVaccine #VaccineInnovation #Immunization #VaccineDevelopment #PublicHealth #VaccineResearch #VaccineMarket #Biotech #Pharmaceuticals #VaccineManufacturing #VaccineDistribution #VaccineEfficacy #VaccineSafety #GlobalHealth #VaccineAwareness #VaccineTechnology #VaccineIndustry #HealthcareInnovation #VaccineCoverage #VaccineAdvancement #VaccineStrategy #VaccinePolicy #VaccineNews #VaccineTrends #HealthTech

🚀 [JOURNÉES SCIENTIFIQUES]

La « reverse vaccinology 3.0 » consiste à utiliser l’intelligence artificielle (#IA) pour prédire des structures antigéniques et d’interactions anticorps-antigène. Elle a notamment mené à l’identification d’une protéine utile à la neutralisation de certaines formes de variole, variole bovine ou variole du singe.

Explications par Dr Emanuele Andreano, Ph.D., head of serology and immunology à la Fondazione Biotecnopolo di Siena, à l’occasion des Journées scientifiques 2026 de l’ANRS Maladies infectieuses émergentes.

Pour suivre l'événement en direct : https://lnkd.in/eMQNpdPr

Pour en savoir plus : https://lnkd.in/ekD8FVqH

#science #santé #recherche #médecine #épidémies

https://lnkd.in/ecjcQx65

The most critical strategy for controlling the spread of infectious diseases is vaccination—making vaccine production processes pivotal to disease control and eventual eradication. Vaccination is an artificial process where inactivated, attenuated infectious pathogens, or their components, are delivered to the human body, using antigenic structures to activate the immune system. This process stimulates an effective response against specific pathogens to combat impending infections.

Since the mid-20th century, viral vaccines have been produced using chicken embryos, with dozens of approved traditional human vaccines manufactured via embryo-based processes. Today, however, cell culture-based vaccine production has become widespread: it enables simple infection and replication in controlled environments, with harvesting steps conducted in closed bioreactor systems to ensure sterility and further reduce biosafety risks through automation. This approach significantly boosts factory capacity, enabling the production of large quantities of vaccine doses.

Sanofi just published their in vivo CAR-T data.

The paper will be published in 𝘔𝘰𝘭𝘦𝘤𝘶𝘭𝘢𝘳 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 this month.

Was this built in-house? Not really. It's the result of two strategic acquisitions that tell you exactly how big pharma is entering in vivo cell engineering.

Everything started about 8 years ago with Sanofi entering the mRNA therapeutics space first.

In 2018, Sanofi partnered with Translate Bio for mRNA vaccines. $45M upfront. Focusing specifically on up to five infectious diseases.

COVID hit.

They expanded the deal in 2020 to $300M cash + $125M as stock investment, covering all infectious diseases.
Then in August 2021, they acquired the whole company for $3.2B!!!

What did they get? One of the largest private LNP libraries in the industry. mRNA manufacturing expertise. A platform ready to go beyond vaccines.

𝘉𝘶𝘵 𝘮𝘙𝘕𝘈 𝘵𝘦𝘤𝘩 𝘢𝘭𝘰𝘯𝘦 𝘥𝘰𝘦𝘴𝘯'𝘵 𝘮𝘢𝘬𝘦 𝘪𝘯 𝘷𝘪𝘷𝘰 𝘊𝘈𝘙-𝘛 𝘸𝘰𝘳𝘬!

Three months before closing Translate Bio, Sanofi acquired Tidal Therapeutics in April 2021. $160M upfront, $470M total including milestones.

𝗦𝗮𝗻𝗼𝗳𝗶'𝘀 𝘁𝗼𝘁𝗮𝗹 𝗰𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁:
+$𝟯.𝟲𝗕 𝘁𝗼 𝗲𝗻𝘁𝗲𝗿 𝘁𝗵𝗲 𝗺𝗥𝗡𝗔 𝗮𝗻𝗱 𝗶𝗻 𝘃𝗶𝘃𝗼 𝗖𝗔𝗥-𝗧 𝘀𝗽𝗮𝗰𝗲

Tidal brought the missing piece: targeted nanoparticle technology to reprogram immune cells directly in the body.

Now the paper shows what happens when you combine both platforms.

The technical execution is solid:

• Proprietary ionizable lipid 15 for T cell transfection
• Anti-CD8 VHH nanobody outperforming other ligands
• CD22 CAR benchmarked against clinically validated CARs (FMC63 and m971)
• Hepatic de-targeting, under 5% liver uptake
• Tumor suppression in aggressive human models

That last point matters. Getting mRNA into T cells is hard enough.

Keeping it away from liver trapping while maintaining efficacy is the real challenge.

They solved both.

This is how platforms get built in 2025. You don't develop everything internally. You acquire the best technology, integrate it fast, and publish validation data within a few years.

Translate Bio gave them the mRNA engine. Tidal gave them the targeting system. Together, they created an in vivo CAR-T platform neither could build alone.

The question now is whether improvements we witness in the in vivo CAR-T space will scale beyond hematological malignancies.

The delivery is transient.
The safety profile looks clean (mRNA).
Serial killing durability up to 8 days.
And repeat dosing gave no signs of toxicity.

Can this match the persistence of ex vivo products?
Will in vivo CAR-T platforms ever be efficacious in solid tumors?

So much money has been invested in this tech and we are seeing progress with creative solutions to optimize in vivo CAR-T platforms.

Pre-print link to the article in the comments!

-----------------------------------------------------------

I share insights on all things xRNA, CAR-X and CGT innovation. Follow me for more biotech insights | 33 comments on LinkedIn

This week’s Global Health Notes looks at how science and policy are shaping disease prevention — from vaccine‑carrying mosquitoes and India’s HPV rollout to new ways countries plan and fund vaccines.

Interesting in Cell Stem Cell: In vivo CAR-Tfh cell reprogramming restores tolerance in a mouse model of autoimmune hepatitis
https://lnkd.in/en36DGSU
Autoimmune diseases involve the coordinated dysregulation of multiple types of immune cells, and single-cell targeted therapies often yield suboptimal results. Here, we developed chimeric antigen receptor (CAR)-engineered follicular helper T (Tfh) cells capable of simultaneously suppressing T cells, B cells, and dendritic cells (DCs) to restore immune homeostasis in an autoimmune hepatitis (AIH) mouse model. Using amino acid-derived lipid nanoparticles, we deliver self-amplifying RNA encoding Forkhead box protein P3 (Foxp3) and a cytochrome P4502D6 (CYP2D6)-specific CAR to Tfh cells, conferring stable regulatory features and antigen-dependent suppressive activity. Engineered CAR-Tfh cells preferentially localize to the liver, recognize CYP2D6-expressing hepatocytes, and suppress pathogenic T cell and B cell responses. In AIH-II mouse models, CAR-Tfh cell generation restores a tolerogenic hepatic immune environment and ameliorates autoimmune liver injury. These findings establish in situ Tfh cell reprogramming as a modular approach to coordinately modulate multiple immune compartments, providing a potential therapeutic framework for AIH and related autoimmune diseases.

Turning mosquitoes into "flying vaccines"? Science is getting creative in the fight against infectious diseases.

A fascinating new line of research explores how mosquitoes could be used to deliver vaccines to wild bats-helping stop dangerous viruses like rabies and Nipah at their source before they spill over into humans.

Here's the idea:

Mosquitoes are engineered to carry a harmless vaccine virus

When they bite bats, they "inject" immunity

Alternative approach: mineral-rich drinking stations with edible vaccines

Why this matters:

Bats are natural reservoirs for many high-risk viruses, and traditional vaccination methods simply don't work at scale in wild populations. Instead of culling (which can backfire), scientists are looking at ecological, non-invasive solutions.

Early results are promising:

Vaccinated animals developed protective antibodies

Bats were successfully immunized via bites,
ingestion, and drinking

Some survived otherwise lethal virus exposure

Of course, big questions remain-especially around environmental safety, regulation, and real-world deployment.

But this approach signals something bigger:
A shift toward stopping pandemics at the source, not just reacting to them.
Innovations like this could redefine how we manage zoonotic diseases in an increasingly interconnected world.

#GlobalHealth #Vaccines #IntegratedPestManagement
#CommercialPestControl
#FoodSafetyStandards
#EnvironmentalHealth #PublicHealthProtection #QualityAssurance
#RiskManagement #BrandProtection #ComplianceManagement #GlobalStandards
#Innovation #OneHealth #PublicHealth
#Science #PandemicPrevention

"Continued Anticomplement #Therapy: A Lifeline for Post-Renal-Transplant Patients with Complement-Mediated Hemolytic Uremic Syndrome"

🖋️ by Natasha Venugopal, Hyma V. Polimera, Jessica Santucci, Erik Washburn and Elizabeth Federici

🔗 https://brnw.ch/21x1a0V

Le Dr Isabelle Nel, PHU en Immunologie biologique à l'Hôpital Robert Debré, a récemment partagé un article sur l'utilisation des anticorps thérapeutiques.

Vous pouvez consulter cet article sur notre site via le lien suivant : https://lnkd.in/ebi4yJYV

𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐢𝐧 𝐕𝐚𝐜𝐜𝐢𝐧𝐞𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dFNjk8eY

The global vaccines market (excluding COVID-19 vaccines), valued at USD 49.59 billion in 2024, stood at USD 47.65 billion in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2030, culminating in a forecasted valuation of USD 67.91 billion by the end of the period.

The market is growing due to several factors, including the rapid development and global commercialization of vaccines, the increasing prevalence of infectious diseases that require vaccination for prevention, the rising number of immunization programs, advancements in technology that support vaccine development, and increased government support through investments and funding aimed at creating new vaccines for various disease indications.

• The North America vaccines market accounted for a 52.3% revenue share in 2024.

• By disease indication, the pneumococcal disease segment is expected to register the highest CAGR of 10.6%.

• By technology, the inactivated & subunit vaccines segment is projected to grow at the fastest rate from 2025 to 2030.

• By end user, the adult vaccines segment accounted for a larger share of 54.0% of the market in 2024.

• Companies such as GSK, Merck Group, Pfizer were identified as some of the star players in the vaccines market (global), given their strong market share and product footprint.

• Companies such as SINOVAC BIOTECH LTD., Incepta Pharmaceuticals Ltd., Valneva among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders

🐄 Understanding Vaccination & Antibody Titre Dynamics in Dairy Cattle 🧬

Effective vaccination is not just about injecting vaccines—it’s about understanding how the immune system responds and how long protection lasts.

🔬 What happens after vaccination?
The animal’s immune system produces antibodies. The first response is slow and low, while booster doses create a faster and stronger immunity.

📊 Antibody Titre Dynamics:
Antibody levels follow a pattern:
➡️ Lag Phase → 📈 Peak → 📉 Decline

This is why timely booster doses are essential to maintain protection.

🐮 Maternal Antibodies in Calves:

- Obtained through colostrum
- Provide early protection
- Can interfere with early vaccination

⏳ Proper timing of vaccination in calves is critical to avoid vaccine failure.

📅 Practical Vaccination Strategy:

- Calves: 3–6 months
- Boosters: 2–4 weeks after first dose
- Adults: Annual or biannual vaccination

⚠️ Factors Affecting Immune Response:

- Nutrition (Protein, Zinc, Selenium)
- Stress & disease conditions
- Proper vaccine storage & handling (cold chain)

🧪 Why Antibody Titre Testing Matters?

- Evaluate vaccine effectiveness
- Monitor herd immunity
- Optimize vaccination programs
(Common method: ELISA)

💡 Key Takeaways:
✔ Boosters are critical
✔ Good nutrition improves immunity
✔ Monitor and adapt vaccination plans

🌱 Strong immunity = Healthy herd = Better productivity

#DairyFarming #HerdHealth #DairyNutrition

From PK regulator to therapeutic breakthrough, FcRn is reshaping autoimmune treatment. With Vyvgart expanding into CIDP and Nipocalimab advancing in SLE and HDFN, the “chemical plasmapheresis” era is accelerating.

As FcRn programs grow, precise control of pH-dependent binding is essential for long-acting mAb design and clinical success.

ACROBiosystems supports FcRn innovation with:
✔ High-quality FcRn proteins
✔ TR-FRET binding kits
✔ Functional cell lines

Enable precision from discovery to IND.

👉 Advance your FcRn program with confidence.

Il n'existe actuellement aucun traitement efficace contre l'insuffisance rénale aiguë, qui est associée à des longues hospitalisations et un taux de (…)

𝗖𝗔𝗥-𝗧 𝗶𝗻 𝘀𝗼𝗹𝗶𝗱 𝘁𝘂𝗺𝗼𝗿𝘀 - 𝗮 𝗿𝗲𝘃𝗶𝗲𝘄

🧠 𝗔 𝗽𝗮𝗽𝗲𝗿 𝗮 𝗱𝗮𝘆 𝗸𝗲𝗲𝗽𝘀 𝗯𝗿𝗮𝗶𝗻 𝗱𝗲𝗰𝗮𝘆 𝗮𝘄𝗮𝘆 🧠
Monday 16 March 2026

𝘚𝘰𝘭𝘪𝘥 𝘵𝘶𝘮𝘰𝘳 𝘊𝘈𝘙-𝘛 𝘤𝘦𝘭𝘭 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 𝘪𝘴 𝘴𝘵𝘢𝘳𝘵𝘪𝘯𝘨 𝘵𝘰 𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘦 𝘳𝘦𝘢𝘭 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭 𝘳𝘦𝘴𝘱𝘰𝘯𝘴𝘦𝘴, 𝘣𝘶𝘵 𝘥𝘶𝘳𝘢𝘣𝘭𝘦 𝘴𝘶𝘤𝘤𝘦𝘴𝘴 𝘸𝘪𝘭𝘭 𝘥𝘦𝘱𝘦𝘯𝘥 𝘰𝘯 𝘰𝘷𝘦𝘳𝘤𝘰𝘮𝘪𝘯𝘨 𝘢𝘯𝘵𝘪𝘨𝘦𝘯 𝘩𝘦𝘵𝘦𝘳𝘰𝘨𝘦𝘯𝘦𝘪𝘵𝘺, 𝘱𝘰𝘰𝘳 𝘵𝘳𝘢𝘧𝘧𝘪𝘤𝘬𝘪𝘯𝘨, 𝘰𝘯-𝘵𝘢𝘳𝘨𝘦𝘵 𝘰𝘧𝘧-𝘵𝘶𝘮𝘰𝘳 𝘵𝘰𝘹𝘪𝘤𝘪𝘵𝘺, 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘴𝘶𝘱𝘱𝘳𝘦𝘴𝘴𝘪𝘷𝘦 𝘵𝘶𝘮𝘰𝘳 𝘮𝘪𝘤𝘳𝘰𝘦𝘯𝘷𝘪𝘳𝘰𝘯𝘮𝘦𝘯𝘵.

💡𝗧𝗮𝗸𝗲 𝗵𝗼𝗺𝗲 𝗺𝗲𝘀𝘀𝗮𝗴𝗲
 • Clinical efficacy: While response rates in solid tumors remain modest overall, clear “pockets of promise” exist in neuroblastoma (GD2), sarcoma (HER2), and glioblastoma (IL-13Rα2), with some trials reporting complete response rates up to ~31%.
 • Biological barriers: Major challenges include antigen heterogeneity, on-target off-tumor toxicity, poor T cell trafficking, and an immunosuppressive tumor microenvironment. The field is moving toward armored CARs (for example IL-12 or IL-15 secreting cells) and logic-gated circuits such as SynNotch to improve specificity and persistence.
 • Manufacturing innovation: New ex vivo strategies — including metabolic priming with L-arginine and shortened vein-to-vein production (24–72 h) — aim to preserve T cell stemness and reduce exhaustion.
 • Emerging platforms: Allogeneic “off-the-shelf” CAR-T products and in vivo CAR engineering using lipid nanoparticles are being explored to overcome scalability and manufacturing complexity.

🔥𝗜𝗺𝗽𝗮𝗰𝘁
 • Future progress will likely come from integrated cell engineering and tumor-specific clinical strategies, not receptor design alone.

❓𝗢𝗽𝗲𝗻 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀
 • Which antigen combinations best balance tumor coverage and safety?
 • Which armored CAR payloads enhance efficacy without systemic toxicity?
 • How should conditioning, delivery route, and combinations differ by tumor type?


𝗖𝘂𝗿𝗿𝗲𝗻𝘁 𝘀𝘁𝗮𝘁𝗲 𝗼𝗳 𝗖𝗔𝗥-𝗧 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗳𝗼𝗿 𝘀𝗼𝗹𝗶𝗱 𝘁𝘂𝗺𝗼𝗿𝘀
Reginaldo Rosa, MBA, PhD et al.
Med, February 2026
Corresponding author: Saul Priceman

🔗 𝘓𝘪𝘯𝘬 𝘵𝘰 𝘵𝘩𝘦 𝘱𝘶𝘣𝘭𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘪𝘯 𝘤𝘰𝘮𝘮𝘦𝘯𝘵𝘴
𝘐𝘭𝘭𝘶𝘴𝘵𝘳𝘢𝘵𝘪𝘰𝘯 𝘢𝘥𝘢𝘱𝘵𝘦𝘥 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘢𝘳𝘵𝘪𝘤𝘭𝘦. 
𝘛𝘩𝘦 𝘰𝘱𝘪𝘯𝘪𝘰𝘯𝘴 𝘴𝘩𝘢𝘳𝘦𝘥 𝘰𝘯 𝘓𝘪𝘯𝘬𝘦𝘥𝘐𝘯 𝘢𝘳𝘦 𝘮𝘺 𝘰𝘸𝘯.
| 11 comments on LinkedIn

You’ve heard of CAR-T.
But you might not know about CAAR-T - a newer, more targeted twist on the same technology:

So what is it?
- CAAR-T (Chimeric AutoAntibody Receptor T cells) are designed to eliminate only the B cells producing harmful autoantibodies, while sparing the rest.
- Instead of using an antibody fragment to find targets (like CAR-T does), CAAR-T cells display an autoantigen on their surface, tricking autoreactive B cells into binding and revealing themselves.

Here’s how they compare:

CAR-T Cells
Advantages:
- Targets all B cells via markers like CD19
- Proven success in cancer and autoimmune diseases (e.g., lupus)
Disadvantages:
- Destroys healthy B cells too, leading to broader immune impact
- Can cause CRS, especially with large-scale immune activation

CAAR-T Cells
Advantages:
- Precisely targets only B cells producing harmful autoantibodies
- Spares healthy B cells, preserving immune function
Disadvantages:
- Requires known autoantigen (e.g., Dsg3, MuSK)
- Limited clinical experience, still early in development

In short:
CAR-T is broad and proven.
CAAR-T is precise and emerging.

Now, I don't see CAAR-T replacing CAR-T.

But for autoantibody-driven diseases, it could offer something we’ve never had before:
A precise strike against the root cause, without wiping out the entire immune arsenal.

Anything else you'd add?
Drop it in the comments. | 31 comments on LinkedIn